Details of the Drug

General Information of Drug (ID: DMK7XYH)

Drug Name
PF-07284890
Synonyms
Tinlorafenib; ARRY-461; Tinlorafenib [USAN]; PF-07284890; JNJ5N2RH5W; AR00504461; UNII-JNJ5N2RH5W; 2573781-75-4; WHO 12353; 1-Propanesulfonamide, N-(2-chloro-3-((3,4-dihydro-3,5-dimethyl-4-oxo-6-quinazolinyl)amino)-4-fluorophenyl)-3-fluoro-; N-(2-chloro-3-((3,5-dimethyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoropropane-1-sulfonamide; tinlorafenib [INN]; ARRY461; CHEMBL5095256; SCHEMBL22831935; GTPL12096; BDBM565133; EX-A7593; HY-147405; CS-0564141; PF07284890; PF-07284890; ARRY-461; US11414404, Ex. # 10
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 1 [1]
Drug Type
Small molecule
Structure
3D MOL 2D MOL
Chemical Identifiers
Formula
C19H19ClF2N4O3S
Canonical SMILES
CC1=C(C=CC2=C1C(=O)N(C=N2)C)NC3=C(C=CC(=C3Cl)NS(=O)(=O)CCCF)F
InChI
InChI=1S/C19H19ClF2N4O3S/c1-11-13(6-7-14-16(11)19(27)26(2)10-23-14)24-18-12(22)4-5-15(17(18)20)25-30(28,29)9-3-8-21/h4-7,10,24-25H,3,8-9H2,1-2H3
InChIKey
VVLVISDSGRHLMB-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
155434855
ChEBI ID
CHEMBL5095256
UNII
JNJ5N2RH5W
DrugBank ID
DB17082
TTD ID
DJ8QW7
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Serine/threonine-protein kinase B-raf (BRAF) TTWCGQT BRAF_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Melanoma
ICD Disease Classification 2C30
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Serine/threonine-protein kinase B-raf (BRAF) DTT BRAF 3.00E-01 0.1 0.2
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04543188) A TWO-PART, PHASE 1A/B, OPEN-LABEL, MULTICENTER TRIAL EVALUATING PHARMACOKINETICS, SAFETY AND EFFICACY OF PF-07284890 (ARRY 461) IN PARTICIPANTS WITH BRAF V600 MUTANT SOLID TUMORS WITH AND WITHOUT BRAIN INVOLVEMENT. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Pfzer